The effect of resveratrol on PCOS

The effects of resveratrol supplementation on hormonal, inflammatory and metabolic in women with PCOS.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017061917139N2

Enrollment

Registered

2017-07-17

Start date

2017-07-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

polycystic ovary syndrome. polycystic ovarian syndrome

Interventions

Intervention 1: Resveratrol(one time a day). Intervention 2: placebo(maltodextrin) one time a day.

Treatment - Drugs

Placebo

Resveratrol(one time a day)

placebo(maltodextrin) one time a day

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: PCOS diagnosis (according to Androgen Excess Society criteria); hyperandrogenism (hirsutism) / hyperandrogenemia (testosterone >70ng/dl) and/or oligomenorrhea (<8 spontaneous menses per year) and/or polycystic ovarian morphology on ultrasound Women aged from 18 to 40 years old; Normal prolactin; normal thyroid function; 17-OH progesterone; No evidence of Androgenic hormone secretor tumors; Cushing's syndrome or acromegaly Exclusion criteria: Use of either oral contraceptives, steroids hormones or other medications that could modify the metabolism 3 months before the onset of the trial.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
(S.H.B.G) Sex Hormon Binding Globolin. Timepoint: Before and 12 weekes after the intervention. Method of measurement: -.;FSH. Timepoint: Before and 6 weekes after the intervention. Method of measurement: ng/ml.;LH. Timepoint: Before and 6 weekes after the intervention. Method of measurement: ng/ml.;Fasting blood sugar. Timepoint: Before and 6 weekes after the intervention. Method of measurement: mg/dl.;Testosterone. Timepoint: Before and 12 weekes after the intervention. Method of measurement: ng/ml.;DHEA-S. Timepoint: Before and 12 weekes after the intervention. Method of measurement: nmol/L.	—

Measure

Time frame

(S.H.B.G) Sex Hormon Binding Globolin. Timepoint: Before and 12 weekes after the intervention. Method of measurement: -.;FSH. Timepoint: Before and 6 weekes after the intervention. Method of measurement: ng/ml.;LH. Timepoint: Before and 6 weekes after the intervention. Method of measurement: ng/ml.;Fasting blood sugar. Timepoint: Before and 6 weekes after the intervention. Method of measurement: mg/dl.;Testosterone. Timepoint: Before and 12 weekes after the intervention. Method of measurement: ng/ml.;DHEA-S. Timepoint: Before and 12 weekes after the intervention. Method of measurement: nmol/L.

—

Secondary

Measure	Time frame
HDL- cholesterol. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;HOMA-insulin resistance. Timepoint: Before and 12 weekes after the intervention. Method of measurement: -.;Hs-CRP. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;C-peptide. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;LDL-Cholesterol. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;Creatinine. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;Total serum cholesterol. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;TG. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;Body composition (FM,FFM). Timepoint: Before and 12 weekes after the intervention. Method of measurement: %.;Insulin levels. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mU/ml.;HbA1C. Timepoint: Before and 12 weekes after the intervention. Method of measurement: %.;Weight. Timepoint: Before and 12 weekes after the intervention. Method of measurement: kg.	—

Measure

Time frame

HDL- cholesterol. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;HOMA-insulin resistance. Timepoint: Before and 12 weekes after the intervention. Method of measurement: -.;Hs-CRP. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;C-peptide. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;LDL-Cholesterol. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;Creatinine. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;Total serum cholesterol. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;TG. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mg/dl.;Body composition (FM,FFM). Timepoint: Before and 12 weekes after the intervention. Method of measurement: %.;Insulin levels. Timepoint: Before and 12 weekes after the intervention. Method of measurement: mU/ml.;HbA1C. Timepoint: Before and 12 weekes after the intervention. Method of measurement: %.;Weight. Timepoint: Before and 12 weekes after the intervention. Method of measurement: kg.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Qorbani

EMRI

mqorbani1379@yahoo.com+98 21 8822 0071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026